Published in Br J Haematol on June 01, 2001
Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol (2011) 2.82
Radioimmunodetection of amyloid deposits in patients with AL amyloidosis. Blood (2010) 1.76
Light chain (AL) amyloidosis: update on diagnosis and management. J Hematol Oncol (2011) 1.48
Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients. Leukemia (2014) 1.06
Current treatment of AL amyloidosis. Haematologica (2009) 0.95
Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach. Haematologica (2013) 0.92
Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis. Blood (2014) 0.77
International uniform response criteria for multiple myeloma. Leukemia (2006) 17.78
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia (2008) 3.41
Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study--Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis (2007) 1.94
Removal of the N-terminal hexapeptide from human beta2-microglobulin facilitates protein aggregation and fibril formation. Protein Sci (2000) 1.83
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia (2012) 1.74
Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia (2011) 1.70
Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum (2008) 1.69
A human mitochondrial ferritin encoded by an intronless gene. J Biol Chem (2001) 1.69
Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia (2012) 1.60
A prognostic classification of myelofibrosis with myeloid metaplasia. Br J Haematol (1988) 1.58
Biological and clinical features of acute lymphoblastic leukaemia with cytoplasmic granules or inclusions: description of eight cases. Br J Haematol (1989) 1.49
Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I/II clinical trial. Blood (1992) 1.49
Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome. Leukemia (2006) 1.45
Neuropathies associated with monoclonal gammapathies. Haematologica (1995) 1.40
Duplication of the der(14) chromosome of a translocation (8;14) in a case of Burkitt's type L3-ALL. Cancer Genet Cytogenet (1992) 1.39
The myelodysplastic syndromes: predictive value of eight prognostic systems in 143 cases from a single institution. Haematologica (1999) 1.38
Reduction of DABS-L-methionine-dl-sulfoxide by protein methionine sulfoxide reductase from polymorphonuclear leukocytes: stereospecificity towards the l-sulfoxide. Ital J Biochem (1995) 1.34
Gastrointestinal amyloidosis: a case of chronic diarrhoea. Eur Rev Med Pharmacol Sci (2009) 1.31
Review: immunoglobulin light chain amyloidosis--the archetype of structural and pathogenic variability. J Struct Biol (2000) 1.31
Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by reverse transcription-polymerase chain reaction analysis of IGH-MMSET fusion transcripts. Cancer Res (2000) 1.28
Quantitative evaluation of erythropoietic activity in dysmyelopoietic syndromes. Br J Haematol (1982) 1.27
Changing clinical presentation of multiple myeloma. Eur J Cancer (1991) 1.24
The ultrastructural localization of factor VIII-antigen in human platelets, megakaryocytes and endothelial cells utilizing a ferritin-labelled antibody. Br J Haematol (1978) 1.21
A diagnostic score for molecular analysis of hereditary autoinflammatory syndromes with periodic fever in children. Arthritis Rheum (2008) 1.20
A partially structured species of beta 2-microglobulin is significantly populated under physiological conditions and involved in fibrillogenesis. J Biol Chem (2001) 1.19
Splenomegalic immunocytoma with circulating hairy cells. Report of eight cases and revision of the literature. Haematologica (1986) 1.19
Natural history of idiopathic refractory sideroblastic anemia. Blood (1988) 1.17
Serum albumin in Hodgkin's disease. Cancer (1985) 1.17
Guidelines for the genetic diagnosis of hereditary recurrent fevers. Ann Rheum Dis (2012) 1.11
Panning phage antibody libraries on cells: isolation of human Fab fragments against ovarian carcinoma using guided selection. Cancer Res (1998) 1.10
Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome. Leukemia (2005) 1.09
Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma. Br J Cancer (2000) 1.09
The role of surgery in the treatment of gastrointestinal lymphomas other than low-grade MALT lymphomas. Haematologica (2000) 1.08
Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis. Proc Natl Acad Sci U S A (1995) 1.08
The new apolipoprotein A-I variant leu(174) --> Ser causes hereditary cardiac amyloidosis, and the amyloid fibrils are constituted by the 93-residue N-terminal polypeptide. Am J Pathol (1999) 1.07
Acute lymphoblastic leukaemia occurring as second malignancy: report of the GIMEMA archive of adult acute leukaemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. Br J Haematol (1999) 1.07
The role of surgery in the multimodal treatment of primary gastric non-Hodgkin's lymphomas. A report of 76 cases and review of the literature. Cancer (1990) 1.07
Monoclonal immunoglobulins with antibody activity in myeloma, macroglobulinemia and related plasma cell dyscrasias. Semin Oncol (1986) 1.01
Primary splenic lymphoma: does it exist? Haematologica (1994) 1.00
Platelet activation by von Willebrand factor requires coordinated signaling through thromboxane A2 and Fc gamma IIA receptor. J Biol Chem (2001) 1.00
Biologic and clinical significance of red cell ferritin. Blood (1983) 1.00
Cardiac and pleuropulmonary AL amyloid imaging with technetium-99m labelled aprotinin. Eur J Nucl Med (1995) 1.00
Immunofluorescent detection of factor VIII-related antigen in human platelets and megakaryoctes. Haemostasis (1974) 1.00
Biosynthesis of glycosaminoglycans in bovine cornea. The effet of uridine diphosphate xylose. Biochem J (1970) 0.99
Holter monitoring in AL amyloidosis: prognostic implications. Pacing Clin Electrophysiol (2001) 0.98
Saporin, a ribosome-inactivating protein used to prepare immunotoxins, induces cell death via apoptosis. Br J Haematol (1996) 0.98
Quality of life in rheumatoid arthritis: impact of disability and lifetime depressive spectrum symptomatology. Clin Exp Rheumatol (2006) 0.97
Evidence that extracellular concentrations of dopamine are regulated by noradrenergic neurons in the frontal cortex of rats. J Neurochem (1994) 0.96
Relevance of class, molecular weight and isoelectric point in predicting human light chain amyloidogenicity. Br J Haematol (1990) 0.95
Use of anti-(beta2 microglobulin) mAb to study formation of amyloid fibrils. Eur J Biochem (1997) 0.95
Study of prognosis in Waldenström's macroglobulinemia: a proposal for a simple binary classification with clinical and investigational utility. Blood (1994) 0.95
Long-term effects of parenteral dichloromethylene bisphosphonate (CL2MBP) on bone disease of myeloma patients treated with chemotherapy. Hematol Oncol (1990) 0.95
Severe pruritus should be a B-symptom in Hodgkin's disease. Cancer (1983) 0.95
Clinical and biological features of acute myeloid leukaemia occurring as second malignancy: GIMEMA archive of adult acute leukaemia. Br J Haematol (2001) 0.94
Juvenile idiopathic haemochromatosis: a life-threatening disorder presenting as hypogonadotropic hypogonadism. Hum Genet (1983) 0.94
Hodgkin's disease prognosis: a directly predictive equation. Lancet (1988) 0.93
Cell kinetics in human malignancies studied with in vivo administration of bromodeoxyuridine and flow cytometry. Cancer Res (1988) 0.93
Iron loading in congenital dyserythropoietic anaemias and congenital sideroblastic anaemias. Br J Haematol (1983) 0.93
An IgM monoclonal protein with multiple serological specificities. Clin Exp Immunol (1979) 0.93
Trend of incidence, subsite distribution and staging of colorectal neoplasms in the 15-year experience of a specialised cancer registry. Ann Oncol (2004) 0.93
A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients. Blood (1980) 0.92
New drug therapy of amyloidoses: resorption of AL-type deposits with 4'-iodo-4'-deoxydoxorubicin. Blood (1995) 0.92
Reversal of nephrotic syndrome due to reactive amyloidosis (AA-type) after excision of localized Castleman's disease. Am J Hematol (1994) 0.92
Sheehan's syndrome with complete bone marrow aplasia: long-term results of substitution therapy with hormones. Br J Haematol (1976) 0.92
Study of three patients with monoclonal gammopathies and 'lupus-like' anticoagulants. Br J Haematol (1989) 0.91
Two Takayasu arteritis patients successfully treated with infliximab: a potential disease-modifying agent? Rheumatology (Oxford) (2005) 0.91
Molecular and functional interactions between tumor necrosis factor-alpha receptors and the glutamatergic system in the mouse hippocampus: implications for seizure susceptibility. Neuroscience (2009) 0.91
Expression, regulation and localisation of dystrophin isoforms in human foetal skeletal and cardiac muscle. Neuromuscul Disord (1999) 0.91
Tyrosine phosphorylation of band 3 protein in Ca2+/A23187-treated human erythrocytes. Biochem J (1996) 0.91
Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects. QJM (2011) 0.90
A prognostic index for multiple myeloma. Br J Cancer (1996) 0.90
Letter: Daunorubicin cardiotoxicity. Lancet (1976) 0.89
Diagnostic approach to and follow-up of difficult cases of AL amyloidosis. Haematologica (1996) 0.89
Amyloid fibrils derived from the apolipoprotein A1 Leu174Ser variant contain elements of ordered helical structure. Protein Sci (2001) 0.89
Scintigraphic imaging and turnover studies with iodine-131 labelled serum amyloid P component in systemic amyloidosis. Eur J Nucl Med (1998) 0.89
The degrees of plasma cell clonality and marrow infiltration adversely influence the prognosis of AL amyloidosis patients. Haematologica (1999) 0.89
On the usefulness of PAS reaction for the prognosis of acute lymphoblastic leukemia. Haematologica (1975) 0.89
Juxtapapillary pancreatic metastasis with obstructive jaundice as isolated recurrence of lung adenocarcinoma. Dig Liver Dis (2007) 0.88
Current concepts on the pathogenesis of systemic amyloidosis. Nephrol Dial Transplant (1996) 0.88
Proliferative activity of bone marrow cells in primary dysmyelopoietic (preleukemic) syndromes. Cancer (1983) 0.88
Interleukin-2 therapy in relapsed acute myelogenous leukemia. Cancer J Sci Am (1997) 0.88
Epsilon-aminocaproic acid for synovectomy in haemophilic patients. Acta Haematol (1972) 0.88